The effect of prolonged glucagon infusions on the urinary excretion of catecholamines and 4-hydroxy-3-methoxymandelic acid and on adrenal medullary tissue levels of catecholamines in patients with severe cardiac disease.
D000313:Adrenal Medulla / Q000187:drug effects / Q000378:metabolism*; D000328:Adult; D000368:Aged; D002855:Chromatography, Thin Layer; D004298:Dopamine / Q000378:metabolism* / Q000652:urine; D004837:Epinephrine / Q000378:metabolism* / Q000652:urine; D005260:Female; D005934:Glucagon / Q000008:administration & dosage / Q000494:pharmacology* / Q000627:therapeutic use; D006333:Heart Failure / Q000188:drug therapy / Q000378:metabolism* / Q000652:urine; D006801:Humans; D007263:Infusions, Parenteral; D008297:Male; D008333:Mandelic Acids / Q000378:metabolism*; D008875:Middle Aged; D009638:Norepinephrine / Q000378:metabolism* / Q000652:urine; D011346:Prochlorperazine / Q000627:therapeutic use; D013997:Time Factors
D008333:Mandelic Acids; D005934:Glucagon; D004298:Dopamine; D009638:Norepinephrine; D011346:Prochlorperazine; D004837:Epinephrine